Vyleesi® product results: 14% growth in prescriptions dispensed over prior quarter – 6 consecutive quarters of double digit growth.
Click here to learn more ›

July 2021

Palatin Announces Presentation at the Eyecelerator@ASCRS Conference

Dry Eye and the Need for Innovation Topics: Melanocortins’ role in resolving inflammation and Phase 2 study results with Palatin’s compound PL9643 for dry eye disease On Track to initiate Phase 3 study calendar Q4 2021 with data expected calendar 2H 2022 Jul 22, 2021, 17:28 ET CRANBURY, N.J., July 22, 2021 /PRNewswire/ — Palatin …

Palatin Announces Presentation at the Eyecelerator@ASCRS Conference Read More »

Palatin Announces Adjournment of Annual Meeting of Stockholders

– Limited to Proposal 3, Amendment to Certificate of Incorporation to Increase Authorized Common Stock – Scheduled to Reconvene August 6, 2021, 9:00 am Eastern Daylight Time Jul 08, 2021, 16:15 ET CRANBURY, N.J., July 8, 2021 /PRNewswire/ — Palatin Technologies, Inc. (“Palatin”) (NYSE American: PTN) announced that its 2021 Annual Meeting of Stockholders that convened …

Palatin Announces Adjournment of Annual Meeting of Stockholders Read More »

Scroll to Top